KINETICOS LIFE SCIENCES MANAGEMENT LLC

Thesis

Kineticos Life Sciences Management LLC is a growth equity and venture capital firm founded in 2007, specializing in the life sciences sector within the United States. The firm's core mission is to improve patient outcomes through strategic investments in high-growth opportunities. Their investment focus spans specialized pharmaceutical services, oncology, neurosciences, rare diseases, and antimicrobial resistance (AMR). Kineticos invests across various stages, from pre-seed to growth equity, with a keen interest in disruptive technologies like cell and gene therapy, gene editing, and mRNA/RNAi. The investment thesis centers on partnering with companies that aim to revolutionize drug development, disease diagnosis, and patient treatment. Their strategy involves an operator-led approach, leveraging deep scientific expertise to foster organic growth and facilitate strategic acquisitions. Notably, the Kineticos Disruptor Fund II closed with $57.3 million in committed capital, targeting early-stage life science companies (Seed to Series B). While specific AUM is not disclosed, the firm has a track record of 19 investments. The typical check size is not publicly disclosed, but their investment approach is flexible based on company needs.

Related lists

• Pre-seed Healthcare investors
• Seed-stage Healthcare investors
• Series A Healthcare investors